What is she best known for?
The fields of study she is best known for:
Iris Behrmann focuses on Glycoprotein 130, Cell biology, Molecular biology, Signal transduction and Janus kinase 1.
The study incorporates disciplines such as JAK-STAT signaling pathway and Oncostatin M in addition to Glycoprotein 130.
Her Cell biology research is multidisciplinary, incorporating perspectives in Death-inducing signaling complex and Fas signaling pathway.
Her biological study spans a wide range of topics, including Fas receptor, Transcription factor, TATA box and Intron.
Iris Behrmann has included themes like Common gamma chain and Cytokine receptor in her Janus kinase 1 study.
Her research investigates the link between STAT3 and topics such as Lymphoma that cross with problems in Cancer research.
Her most cited work include:
- Principles of interleukin (IL)-6-type cytokine signalling and its regulation. (2470 citations)
- Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. (1879 citations)
- INTERLEUKIN-6-TYPE CYTOKINE SIGNALLING THROUGH THE GP130/JAK/STAT PATHWAY (1788 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Cell biology, Signal transduction, Cancer research, Molecular biology and Glycoprotein 130.
The various areas that she examines in her Cell biology study include Receptor, Downregulation and upregulation and stat.
Her study explores the link between Signal transduction and topics such as Transcription factor that cross with problems in Regulation of gene expression.
Her Cancer research research incorporates elements of SOCS3, Cytokine, Cell growth and Oncostatin M.
The Molecular biology study combines topics in areas such as Leukemia Inhibitory Factor Receptor alpha Subunit, Receptor complex, STAT3, STAT protein and Antibody.
Her Glycoprotein 130 study integrates concerns from other disciplines, such as Janus kinase 1, Receptor tyrosine kinase, JAK-STAT signaling pathway and Suppressor of cytokine signalling.
She most often published in these fields:
- Cell biology (35.19%)
- Signal transduction (31.48%)
- Cancer research (30.56%)
What were the highlights of her more recent work (between 2012-2020)?
- Cytokine (23.15%)
- Cancer research (30.56%)
- Cell biology (35.19%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Cytokine, Cancer research, Cell biology, microRNA and Immunology.
Her Cytokine study combines topics from a wide range of disciplines, such as Cancer cell, STAT3, Signal transduction and Liver cancer.
Her research integrates issues of GNMT, Blocking antibody, Janus kinase and Oncostatin M in her study of Cancer research.
Her work carried out in the field of Janus kinase brings together such families of science as Cell growth, Janus Kinase Family, Molecular biology and Cell cycle, Aurora inhibitor.
Her Cell biology research focuses on Downregulation and upregulation and how it connects with Mitochondrion.
She focuses mostly in the field of Transcription factor, narrowing it down to topics relating to Reporter gene and, in certain cases, Glycoprotein 130.
Between 2012 and 2020, her most popular works were:
- MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. (87 citations)
- New Target Genes of MITF-Induced microRNA-211 Contribute to Melanoma Cell Invasion (58 citations)
- Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? (58 citations)
In her most recent research, the most cited papers focused on:
Iris Behrmann mostly deals with microRNA, Cell biology, Cancer research, Melanoma and Downregulation and upregulation.
Her microRNA study which covers Cancer that intersects with Methyltransferase and Biomarker.
Her Cell biology study integrates concerns from other disciplines, such as Cancer cell, Secretion and Extracellular vesicle.
Iris Behrmann incorporates Cancer research and TRPM1 in her studies.
Her research investigates the connection between Downregulation and upregulation and topics such as Phosphorylation that intersect with problems in Kinase.
Her Janus kinase 2, Janus kinase inhibitor and Janus kinase study in the realm of Kinase connects with subjects such as Ruxolitinib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
